Redhill Biopharma Ltd Cash Flow Conversion Efficiency
Redhill Biopharma Ltd cash flow conversion efficiency. Based on the latest financial reports, Redhill Biopharma Ltd (RDHL) has a cash flow conversion efficiency ratio of 0.568x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.51 Million) by net assets ($-4.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Redhill Biopharma Ltd (2010–2025)
Cash flow conversion efficiency of Redhill Biopharma Ltd from 2010 to 2025. This chart illustrates how Redhill Biopharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View RDHL share price today for real-time trading data and today's change.
Redhill Biopharma Ltd Cash Flow Conversion Ratio Explained
Redhill Biopharma Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Redhill Biopharma Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Redhill Biopharma Ltd ranked by their cash flow conversion efficiency. Also see market value of Redhill Biopharma Ltd for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SQX Resources Ltd
AU:SQX
|
0.000x |
|
Jianzhi Education Technology Group Company Limited American Depositary Shares
NASDAQ:JZ
|
0.428x |
|
Smooth Rock Ventures Corp
V:SMRV
|
-0.028x |
|
NORTHERN SHIELD RES INC.
F:N9SA
|
N/A |
|
Omega Therapeutics Inc
NASDAQ:OMGA
|
-1.214x |
|
GSS Infotech Limited
NSE:GSS
|
-0.041x |
|
Calidi Biotherapeutics Inc.
NYSE MKT:CLDI
|
-1.342x |
|
Precomp Solutions AB Series B
ST:PCOM-B
|
-0.069x |
Annual Cash Flow Conversion Efficiency for Redhill Biopharma Ltd (2010–2025)
The table below shows the annual cash flow conversion efficiency of Redhill Biopharma Ltd from 2010 to 2025. Review how much free cash does Redhill Biopharma Ltd generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.27 Million | $-9.65 Million | -2.261x | -213.03% |
| 2024-12-31 | $-4.68 Million | $-9.37 Million | 2.001x | +111.56% |
| 2023-12-31 | $2.07 Million | $-35.82 Million | -17.313x | -2971.10% |
| 2022-12-31 | $-48.40 Million | $-29.18 Million | 0.603x | +108.23% |
| 2021-12-31 | $8.88 Million | $-65.05 Million | -7.329x | -109.17% |
| 2020-12-31 | $13.86 Million | $-48.58 Million | -3.504x | -415.95% |
| 2019-12-31 | $60.00 Million | $-40.75 Million | -0.679x | -0.87% |
| 2018-12-31 | $51.19 Million | $-34.46 Million | -0.673x | +32.23% |
| 2017-12-31 | $45.06 Million | $-44.77 Million | -0.993x | -120.43% |
| 2016-12-31 | $62.70 Million | $-28.26 Million | -0.451x | -51.89% |
| 2015-12-31 | $60.08 Million | $-17.83 Million | -0.297x | +39.31% |
| 2014-12-31 | $25.01 Million | $-12.23 Million | -0.489x | +30.88% |
| 2013-12-31 | $11.93 Million | $-8.44 Million | -0.707x | -97.99% |
| 2012-12-31 | $19.02 Million | $-6.79 Million | -0.357x | -43.09% |
| 2011-12-31 | $18.79 Million | $-4.69 Million | -0.250x | -124.39% |
| 2010-12-31 | $-1.59 Million | $-1.63 Million | 1.024x | -- |
About Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for … Read more